Infections
Cellulitis is a common bacterial skin infection involving the deeper dermis and subcutaneous fat, typically caused by Streptococcus pyogenes (Group A Strep) and Staphylococcus aureus. Management requires appropriate antibiotic selection based on severity, patient factors, and local resistance patterns, with emphasis on distinguishing between uncomplicated and complicated presentations.
🎯 Understanding Cellulitis Classification
Differentiating between uncomplicated and complicated cellulitis guides treatment decisions:
🔥 Uncomplicated Cellulitis
- Definition: Localized infection WITHOUT systemic symptoms
- Common pathogens: Streptococcus pyogenes (70-80%), MSSA (methicillin-sensitive S. aureus)
- Presentation: Erythema (redness), warmth, swelling, pain, NO fever
- Treatment setting: Outpatient management (home)
- Duration: 5-7 days typically (extends to 10 if slow response)
- Prognosis: Excellent with appropriate oral antibiotics
- Key Point: MOST cellulitis cases are uncomplicated and outpatient-manageable
📈 Complicated Cellulitis
- Definition: Systemic symptoms, comorbidities, or special sites involved
- Risk factors: Diabetes, immunocompromise, lymphedema, venous insufficiency
- Presentation: Fever, tachycardia, extensive involvement, rapid progression
- Treatment setting: Often requires hospitalization (IV antibiotics)
- Duration: 10-14 days or longer (IV then oral)
- Monitoring: Close follow-up, possible infectious disease consult
- Key Point: These patients need aggressive management and monitoring
📉 Special Considerations & MRSA Risk
- Facial cellulitis: Broader coverage needed (oral anaerobes)
- Periorbital/orbital: Ophthalmology consult required
- Animal/human bites: Pasteurella, Eikenella coverage needed
- Water exposure: Vibrio, Aeromonas considerations
- MRSA risk factors: IV drug use, recent hospitalization, nursing home resident
- Key Point: Tailor therapy to specific scenario and risk factors
🎯 Clinical Memory Aid: Remember "S. pyogenes First"
- Most cellulitis (70-80%): Streptococcus pyogenes (Group A Strep)
- Second most common: Staphylococcus aureus (MSSA)
- MRSA: Community-acquired MRSA (CA-MRSA) in specific risk groups only
- Key Principle: Target Strep FIRST, add MRSA coverage only if risk factors present
💊 Outpatient Management
Oral antibiotic regimens for uncomplicated cellulitis (MOST patients):
💊 First-line Oral Therapy (Strep Coverage)
- Cephalexin (Keflex): 500 mg QID (4x daily) for 5-7 days
- Dicloxacillin: 500 mg QID for 5-7 days
- Amoxicillin-clavulanate (Augmentin): 875/125 mg BID for 7-10 days
- Coverage: MSSA and Streptococcus species (including S. pyogenes)
- Monitoring: Clinical improvement expected within 48 hours
- Key Point: These cover 90% of uncomplicated cellulitis cases
🦠 MRSA-Coverage Oral Therapy
- Clindamycin: 300-450 mg TID-QID for 7-10 days
- Doxycycline: 100 mg BID for 7-10 days
- Trimethoprim-sulfamethoxazole (TMP-SMX): 1-2 DS tablets BID for 7-10 days
- Linezolid (Zyvox): 600 mg BID for 10-14 days (expensive, reserve)
- Indications: MRSA risk factors present or confirmed MRSA
- Key Point: Usually combined with Strep coverage (dual therapy)
⚠️ Penicillin Allergy Options
- Non-severe allergy: Cephalexin (cross-reactivity <10%)
- Severe allergy (anaphylaxis): Clindamycin, Doxycycline, TMP-SMX
- Macrolides: Azithromycin, Clarithromycin (resistance common, 2nd-line)
- Monitoring: Watch for C. difficile with clindamycin
- Key Point: 90% of "penicillin allergic" patients can tolerate cephalosporins
🤗 Supportive Care (CRITICAL)
- Elevation: Reduce dependent edema (MOST important supportive measure)
- Cool compresses: Symptomatic relief of pain and swelling
- Analgesics: NSAIDs (ibuprofen) or acetaminophen for pain
- Hydration: Adequate fluid intake essential
- Wound care: Keep area clean and dry, cover if draining
- Follow-up: Re-evaluate in 48-72 hours for improvement
⚠️ CRITICAL WARNING: Elevation is AS IMPORTANT as antibiotics for extremity cellulitis. Failure to elevate leads to treatment failure, prolonged symptoms, and increased recurrence risk. Educate patients: "Keep it higher than your heart."
🏥 Inpatient Management
Intravenous therapy for complicated or severe cellulitis (hospitalization required):
⚡ Indications for Hospitalization
- Systemic toxicity: Fever >38.5°C, tachycardia, hypotension
- Rapid progression: Despite 48 hours of appropriate oral antibiotics
- Significant comorbidities: Diabetes, immunocompromise, heart failure
- Special locations: Facial, periorbital, genital involvement
- Inability to tolerate oral: Nausea, vomiting, altered mental status
- Social factors: Homelessness, non-adherence concerns, lack of follow-up
💉 Initial IV Therapy Regimens
- Standard coverage (no MRSA risk): Cefazolin 1-2 g IV q8h
- Penicillin allergy: Clindamycin 600-900 mg IV q8h
- MRSA coverage needed: Vancomycin 15-20 mg/kg IV q8-12h (trough 10-20)
- Broad spectrum (facial/polymicrobial): Piperacillin-tazobactam or Carbapenems
- Duration: IV until improved (2-5 days), then complete 10-14 days oral
- Key Point: Step down to oral as soon as possible (within 48-72 hours)
🔬 Important Diagnostic Considerations
- Blood cultures: Low yield in uncomplicated cellulitis (<5% positive); do if systemic symptoms Higher yield in immunocompromised, IV drug users, severe cases
- Mark borders: Use pen to outline erythema edges to objectively monitor progression Expected improvement within 24-48 hours of appropriate antibiotics
- Consider underlying conditions: Tinea pedis (athlete's foot), venous insufficiency, lymphedema Treat these to prevent recurrence
- Assess for abscess: Ultrasound if fluctuant area; requires drainage (I&D) Antibiotics alone won't cure abscess - must drain
- Non-infectious mimics: Stasis dermatitis, DVT (deep vein thrombosis), gout, contact dermatitis Bilateral involvement suggests stasis dermatitis, not cellulitis
🚨 IMPORTANT HOSPITAL MANAGEMENT CONSIDERATIONS:
- Vancomycin trough monitoring: Check levels before 4th dose, target 10-20 mg/L
- Renal function monitoring: Vancomycin is nephrotoxic, adjust for renal impairment
- Early switch to oral: When afebrile 24-48h, improved clinically, tolerating oral
- Infectious disease consult: For complicated cases, treatment failures, unusual pathogens
- Surgical consult: If necrotizing infection suspected, abscess present, or worsening despite antibiotics
- Discharge planning: Ensure follow-up, home care instructions, understanding of oral regimen
📊 Antibiotic Selection Guide
| Clinical Scenario | First-line Therapy | Alternative Options | Duration | Special Considerations |
|---|---|---|---|---|
| Uncomplicated Cellulitis (Outpatient) |
Cephalexin 500 mg QID | Dicloxacillin 500 mg QID Amox-Clav 875/125 mg BID |
5-7 days | Re-evaluate in 48h; extend to 10d if slow response |
| MRSA Suspected (Outpatient with risk factors) |
TMP-SMX 1-2 DS BID + Cephalexin | Clindamycin 300-450 mg QID Doxycycline 100 mg BID |
7-10 days | Dual therapy covers both MRSA AND Streptococcus |
| Hospitalized - No MRSA Risk | Cefazolin 1-2 g IV q8h | Oxacillin 2 g IV q4h Clindamycin 600 mg IV q8h |
IV 2-5d, then oral to complete 7-14d total | Switch to oral when afebrile 24-48h, clinically improved |
| Hospitalized - MRSA Risk | Vancomycin 15-20 mg/kg IV q8-12h | Daptomycin 4-6 mg/kg IV daily Linezolid 600 mg IV/PO q12h |
IV 3-7d, then oral to complete 10-14d total | Monitor vancomycin trough (10-20), renal function |
| Facial Cellulitis (Dental/sinus source) |
Amox-Clav 875/125 mg PO BID or IV equivalent | Vancomycin + Pip-Tazo IV Clindamycin + Levofloxacin |
7-14 days | Consider dental source, broader coverage for oral anaerobes |
| Animal/Human Bites | Amox-Clav 875/125 mg PO TID | Doxycycline 100 mg BID + Metronidazole 500 mg TID | 7-14 days | Cover Pasteurella (cats/dogs), Eikenella (human bites), anaerobes |
| Water Exposure (Salt/fresh water) |
Doxycycline 100 mg BID + Ceftazidime 2 g IV q8h | Ciprofloxacin 400 mg IV q12h Levofloxacin 750 mg PO/IV daily |
7-14 days | Cover Vibrio (saltwater), Aeromonas (freshwater) - can be rapidly progressive |
🔥 HIGH-YIELD: Antibiotic Pearls for Cellulitis
- Strep first: Most cellulitis is Streptococcus (70-80%), not Staph
- MRSA targeted: Only cover MRSA if risk factors or confirmed
- Cephalexin: 500 mg QID (not TID) - higher dose needed for good tissue penetration
- Dual therapy: TMP-SMX (covers MRSA) + Cephalexin (covers Strep) for MRSA risk
- Short courses: 5-7 days usually sufficient; extend only if slow response
- Elevation: As important as antibiotics for extremity cellulitis
👁️ Special Site Considerations
Management of cellulitis in specific anatomical locations (requires special attention):
👁️ Periorbital vs Orbital Cellulitis
- Periorbital (preseptal): Anterior to orbital septum Eyelid swollen but eye moves normally, vision normal
- Orbital (postseptal): Behind orbital septum - TRUE EMERGENCY Proptosis (eye bulging), ophthalmoplegia (eye movement limited), vision changes
- Differentiation: CT scan often needed to distinguish Orbital = surgical emergency with ophthalmology/ENT consult
- Periorbital treatment: Oral antibiotics if mild, IV if severe Amox-Clav or Clindamycin; close ophthalmology follow-up
- Orbital treatment: IV antibiotics (Vancomycin + Pip-Tazo), surgical drainage Hospitalize, monitor vision hourly, prepare for surgery
- Key Point: Orbital cellulitis can cause blindness and intracranial spread
🦵 Lower Extremity Cellulitis
- Common triggers: Tinea pedis (athlete's foot), trauma, venous insufficiency Interdigital fungal infection is most common portal of entry
- Bilateral involvement: Consider stasis dermatitis instead True cellulitis is usually unilateral; bilateral suggests venous stasis
- Treatment adjuncts: Elevation CRUCIAL, treat underlying tinea (topical antifungals) Compression stockings AFTER acute inflammation resolves (2-4 weeks)
- Recurrent cases: Consider penicillin prophylaxis (250 mg BID) After ≥2 episodes in 1 year; reduces recurrence by 45%
- Key Point: Address predisposing factors or recurrence inevitable
🔍 CRITICAL CLINICAL INSIGHT: Facial cellulitis often has dental or sinus origin and requires broader coverage including oral anaerobes. Always check for dental pain, sinus symptoms, or recent dental procedures. These infections can spread to cavernous sinus (life-threatening) or cause airway compromise.
Mnemonic: "FACE = Find And Cover Everything" (broader antibiotic coverage needed)
Mnemonic: "FACE = Find And Cover Everything" (broader antibiotic coverage needed)
⚠️ Complications & Recurrent Cases
Management of complications and prevention strategies for recurrent cellulitis:
📉 Common Complications
- Abscess formation: Requires incision and drainage (I&D) Antibiotics alone insufficient; surgical drainage mandatory
- Necrotizing fasciitis: Surgical emergency - pain OUT OF PROPORTION Skin may look normal early; high mortality (30-50%)
- Bacteremia: Blood cultures positive in severe cases (5-10%) Higher in immunocompromised, IV drug users
- Sepsis: Organ dysfunction from infection (SIRS criteria) Requires ICU care, broad-spectrum antibiotics
- Chronic lymphedema: From lymphatic damage Creates vicious cycle: lymphedema → more cellulitis → more lymphedema
- Recurrence: Common without addressing predisposing factors (30-50% recurrence rate)
🚨 RED FLAGS REQUIRING IMMEDIATE ATTENTION (Necrotizing Fasciitis):
- Severe pain out of proportion to examination findings
- Rapid progression with dusky, purple, or black skin discoloration
- Skin necrosis or hemorrhagic bullae (blood-filled blisters)
- Systemic toxicity with altered mental status, hypotension
- Gas in tissues on examination (crepitus) or imaging
- "Woody" hardness of tissues beyond erythema borders
- ACTION: Immediate surgical consultation, broad-spectrum antibiotics (Vanco + Pip-Tazo + Clinda), ICU admission
🎯 Prevention Strategies
Evidence-based approaches to reduce cellulitis incidence and recurrence:
💉 Primary Prevention
- Skin integrity maintenance: Moisturize dry skin, treat eczema Broken skin is portal for bacteria
- Proper foot care: Treat tinea pedis, keep feet dry, proper footwear Interdigital spaces common entry point
- Wound care: Clean and cover cuts, scrapes, insect bites Prevents bacterial colonization
- Lymphedema management: Early compression, lymphatic massage Reduces stagnation of lymph fluid
🛡️ Secondary Prevention
- Penicillin prophylaxis: 250-500 mg BID after ≥2 episodes in 1 year Most effective preventive measure (45% reduction)
- Compression stockings: Properly fitted, worn daily Reduces edema, improves lymphatic flow
- Patient education: Recognize early signs, seek immediate treatment Reduces severity and complications
- Treat comorbidities: Control diabetes, improve venous insufficiency Reduces susceptibility to infection
📋 Tertiary Prevention
- Lymphatic surgery: For severe, refractory lymphedema Reduces recurrence frequency
- Multidisciplinary care: Dermatology, vascular, infectious disease For complex or recurrent cases
- Psychological support: Chronic recurrent infections affect quality of life Depression common with frequent recurrences
- Regular follow-up: Monitor for early signs of recurrence Especially during prophylaxis treatment
🩺 PROPHYLAXIS INDICATIONS: Consider penicillin prophylaxis after:
- ≥2 episodes of cellulitis in same area within 1 year
- Severe episode requiring hospitalization
- Significant comorbidities that increase complication risk (lymphedema, diabetes)
- Occupational/social impact from recurrent infections
- Duration: Typically 6-12 months, then reassess; some need lifelong
- Monitoring: Regular follow-up, watch for side effects, assess continued need
🧠 Key Pharmacologic Principles
Essential considerations for understanding and managing cellulitis:
🎯 CLINICAL DECISION ALGORITHM:
- Step 1: Assess severity → Uncomplicated vs Complicated (needs hospitalization?)
- Step 2: Outpatient: First-line = Cephalexin 500 mg QID x 5-7 days
- Step 3: Add MRSA coverage ONLY if risk factors: TMP-SMX + Cephalexin
- Step 4: CRITICAL: Elevate extremity, mark borders, follow-up in 48h
- Step 5: Hospitalized: Vancomycin (if MRSA risk) or Cefazolin (if no MRSA risk)
- Step 6: Step down to oral when: Afebrile 24-48h, clinically improving, tolerating oral
- Step 7: Prevention: Address underlying factors, consider prophylaxis if recurrent
⚠️ COMMON PITFALLS TO AVOID:
- Over-treating MRSA: Most cellulitis is Streptococcus, not MRSA
- Missing abscess: Antibiotics won't cure abscess - needs drainage
- Ignoring elevation: Failure to elevate leads to treatment failure
- Not marking borders: Can't objectively assess improvement
- Overlooking predisposing factors: Leads to recurrence
- Missing necrotizing infection: Pain out of proportion is KEY sign
- Confusing stasis dermatitis: Bilateral, chronic, not acutely tender
🧭 Conclusion
Effective management of cellulitis requires understanding that most cases (70-80%) are caused by Streptococcus pyogenes, not Staphylococcus aureus. First-line therapy for uncomplicated cellulitis should target Streptococcus with agents like cephalexin or dicloxacillin, reserving MRSA coverage for patients with specific risk factors or confirmed MRSA infection.
Supportive measures, particularly elevation of the affected extremity, are as crucial as antibiotic therapy for successful treatment. Marking the borders of erythema provides objective assessment of treatment response, with improvement expected within 48 hours of appropriate therapy.
Hospitalization is warranted for systemic toxicity, rapid progression, significant comorbidities, or special site involvement. Initial IV therapy should be tailored to local resistance patterns and individual risk factors, with prompt transition to oral therapy once clinical improvement occurs.
Recurrent cellulitis requires systematic evaluation and management of predisposing factors such as tinea pedis, venous insufficiency, or lymphedema. Prophylactic penicillin significantly reduces recurrence rates in appropriately selected patients.
Recognition of red flags for necrotizing fasciitis - particularly pain out of proportion to examination findings - ensures timely surgical intervention for this life-threatening condition.
Cellulitis management balances targeted therapy with preventive strategies — treat the current infection appropriately while addressing underlying factors to prevent recurrence. This approach optimizes outcomes, reduces antibiotic resistance, and improves patients' quality of life by breaking the cycle of recurrent skin infections.